Show simple item record

AuthorSkenderi, Faruk
AuthorPalazzo, Juan
AuthorSwensen, Jeffrey
AuthorFeldman, Rebecca
AuthorContreras, Elma
AuthorFlorento, Elena
AuthorGatalica, Zoran
AuthorVranic, Semir
Available date2020-04-14T07:42:23Z
Publication Date2020-04-11
Publication NameThe Breast Journal
Identifierhttp://dx.doi.org/10.1111/tbj.13842
CitationSkenderi, F, Palazzo, J, Swensen, J, et al. Novel targetable biomarkers in clear cell carcinoma of the breast uncovered by molecular profiling: A study of nine cases. Breast J. 2020; 00: 1– 3. https://doi.org/10.1111/tbj.13842
URIhttp://hdl.handle.net/10576/14122
AbstractWe profiled nine pure clear cell carcinomas of the breast using massively parallel DNA and RNA sequencing (NGS), in situ hybridization (ISH), and immunohistochemistry (IHC). All cases were primary mammary clear cell carcinomas that were diagnosed in female patients (mean age: 53.4 years; range: 31-69 years). Based on our findings, we conclude that the majority of clear cell carcinomas are ER/PR positive and consequently amenable to anti-ER treatment modalities. A subset of clear cell carcinomas also harbored alterations in PIK3CA/PTEN/AKT pathway, particularly PTEN, indicating a potential benefit of PI3K/Akt/mTOR inhibitors. The status of I-O biomarkers in clear cell carcinomas indicates a limited therapeutic benefit of immune checkpoint inhibitors (against PD-1/PD-L1).
Languageen
PublisherWiley
Subjectbreast cancer
clear cell carcinoma
immunotherapy
molecular profiling
targeted therapy
TitleNovel targetable biomarkers in clear cell carcinoma of the breast uncovered by molecular profiling: A study of nine cases.
TypeArticle


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record